These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 28854066)

  • 41. Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes.
    Kobayashi E; Naito Y; Asano N; Maejima A; Endo M; Takahashi S; Megumi Y; Kawai A
    Jpn J Clin Oncol; 2019 Oct; 49(10):938-946. PubMed ID: 31365116
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study.
    Nakamura T; Tsukushi S; Asanuma K; Katagiri H; Ikuta K; Nagano A; Kozawa E; Yamada S; Shido Y; Yamada K; Kawanami K; Ishimura D; Sudo A; Nishida Y
    Clin Exp Metastasis; 2019 Aug; 36(4):343-350. PubMed ID: 31209624
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.
    O'Sullivan Coyne G; Walsh J; Kelly CM
    Expert Opin Drug Saf; 2012 Jul; 11(4):643-50. PubMed ID: 22694309
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer.
    Liu B; Liu L; Ran J; Xie N; Li J; Xiao H; Yang X; Tian C; Wu H; Lu J; Gao J; Hu X; Cao M; Shui Z; Hu ZY; Ouyang Q
    ESMO Open; 2023 Jun; 8(3):101563. PubMed ID: 37285718
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates.
    Haddox CL; Nathenson MJ; Mazzola E; Lin JR; Baginska J; Nau A; Weirather JL; Choy E; Marino-Enriquez A; Morgan JA; Cote GM; Merriam P; Wagner AJ; Sorger PK; Santagata S; George S
    Clin Cancer Res; 2024 Apr; 30(7):1281-1292. PubMed ID: 38236580
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.
    Rau KM; Ou-Yang F; Chao TC; Kuo YL; Cheng TF; Chao TY; Chen DR; Tzeng YD; Wang BW; Liu CY; Hu MH; Lu YC; Ou WJ; Kuo CH; Chuang CH; Kan JY; Chen FM; Hou MF
    Breast Cancer Res Treat; 2018 Aug; 170(3):583-591. PubMed ID: 29623575
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas.
    Noujaim J; Alam S; Thway K; Jones RL
    Indian J Med Paediatr Oncol; 2016; 37(3):125-30. PubMed ID: 27688604
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
    Scarpace SL
    Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.
    Wiemer EAC; Wozniak A; Burger H; Smid M; Floris G; Nzokirantevye A; Sciot R; Sleijfer S; Schöffski P
    Eur J Cancer; 2017 Apr; 75():33-40. PubMed ID: 28214655
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient.
    Miano ST; Francini E; Petrioli R; Francini G
    Future Oncol; 2020 Jan; 16(1s):33-38. PubMed ID: 31975628
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618.
    Arnold SM; Moon J; Williamson SK; Atkins JN; Ou SH; LeBlanc M; Urba SG
    Invest New Drugs; 2011 Apr; 29(2):352-9. PubMed ID: 19937365
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.
    Cortes J; Hudgens S; Twelves C; Perez EA; Awada A; Yelle L; McCutcheon S; Kaufman PA; Forsythe A; Velikova G
    Breast Cancer Res Treat; 2015 Dec; 154(3):509-20. PubMed ID: 26567010
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting.
    Mougalian SS; Copher R; Kish JK; McAllister L; Wang Z; Broscious M; Garofalo D; Radtchenko J; Feinberg BA
    Cancer Med; 2018 Sep; 7(9):4371-4378. PubMed ID: 30066497
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry.
    Pouwels XGLV; Geurts SME; Ramaekers BLT; Erdkamp F; Vriens BEPJ; Aaldering KNA; van de Wouw AJ; Dercksen MW; Smilde TJ; Peters NAJB; Riel JMV; Pepels MJ; Heijnen-Mommers J; Joore MA; Tjan-Heijnen VCG; de Boer M
    Acta Oncol; 2020 Jan; 59(1):82-89. PubMed ID: 31583931
    [No Abstract]   [Full Text] [Related]  

  • 55. Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma.
    Martorana F; Vigneri P; Manzella L; Tirrò E; Soto Parra HJ
    Future Oncol; 2020 Jan; 16(1s):9-13. PubMed ID: 31916463
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study.
    Oruc Z; Kaplan MA; Geredeli C; Yildirim Sari N; Ozaslan E; Aytekin A; Tamer Elkiran E; Koca S; Dogan M; Turan N; Yuce O; Sevinc A; Ercelep O; Isikdogan A
    J BUON; 2019; 24(5):1876-1883. PubMed ID: 31786850
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting.
    Inoue K; Takahashi M; Mukai H; Yamanaka T; Egawa C; Sakata Y; Ikezawa H; Matsuoka T; Tsurutani J
    Invest New Drugs; 2020 Oct; 38(5):1540-1549. PubMed ID: 31950374
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.
    Hersh EM; Del Vecchio M; Brown MP; Kefford R; Loquai C; Testori A; Bhatia S; Gutzmer R; Conry R; Haydon A; Robert C; Ernst S; Homsi J; Grob JJ; Kendra K; Agarwala SS; Li M; Clawson A; Brachmann C; Karnoub M; Elias I; Renschler MF; Hauschild A
    Ann Oncol; 2015 Nov; 26(11):2267-74. PubMed ID: 26410620
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients.
    Quaquarini E; Sottotetti F; D'Ambrosio D; Malovini A; Morganti S; Marinello A; Pavesi L; Frascaroli M
    Future Oncol; 2017 Apr; 13(11s):11-23. PubMed ID: 28481185
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial.
    Donoghue M; Lemery SJ; Yuan W; He K; Sridhara R; Shord S; Zhao H; Marathe A; Kotch L; Jee J; Wang Y; Zhou L; Adams WM; Jarral V; Pilaro A; Lostritto R; Gootenberg JE; Keegan P; Pazdur R
    Clin Cancer Res; 2012 Mar; 18(6):1496-505. PubMed ID: 22282463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.